Latest Myeloproliferative disease Stories
Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease's progression.
Myeloproliferative neoplasms (MPN) comprise a family of blood cancers characterized by clonal expansion of a single blood cell type.
WHITE PLAINS, N.Y., July 12 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced it has awarded two new grants through its prestigious Marshall A.
SAN DIEGO, June 30 /PRNewswire/ -- TargeGen, Inc., a privately held biotechnology company focused on the development of small molecule kinase inhibitors today announced that the Company has agreed to be acquired by sanofi-aventis (EURONEXT: SAN; NYSE: SNY).
SINGAPORE, June 9 /PRNewswire/ -- S*BIO Pte Ltd today announced that it has completed enrollment of patients in two separate Phase 2 clinical trials for its potent and orally-active JAK2 inhibitor SB1518 at multiple clinical sites in the U.S.
SINGAPORE and EMERYVILLE, Calif., May 4 /PRNewswire-FirstCall/ -- S*BIO Pte Ltd and Onyx Pharmaceuticals, Inc.
FRIMLEY, England, December 8 /PRNewswire/ -- - Nilotinib Surpassed imatinib in Key Measures of Treatment Effectiveness in the Trial, in Patients With Newly-Diagnosed Disease(1) - At 12-Months, Significantly Fewer Patients Progressed to Later Stages of the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than on imatinib 400mg Once-Daily(1) - Nilotinib was Generally Well Tolerated; Only a Small Number of Patients Discontinued Due to Adverse Events(1) -...
Leukemia and myeloproliferative disorders are serious and often deadly blood cancers.
Drug shrinks swollen spleens, improves quality of life, relieves symptoms in bone marrow disease.
NEW ORLEANS, Dec. 5 /PRNewswire-USNewswire/ -- Leukemia and myeloproliferative disorders are serious and often deadly blood cancers.